利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.034 秒)

    Therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia
    3.
    发明授权
    Therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia 失效

    公开(公告)号：US07354949B2

    公开(公告)日：2008-04-08

    申请号：US10472148

    申请日：2002-03-29

    申请人： Tsuyoshi Yamagata ,  Kaoru Atsuki ,  Tetsuji Ohno ,  Shiro Shirakura ,  Akira Karasawa

    发明人： Tsuyoshi Yamagata ,  Kaoru Atsuki ,  Tetsuji Ohno ,  Shiro Shirakura ,  Akira Karasawa

    IPC分类号： A61K31/38 ,  A61K31/44 ,  A61K31/42

    CPC分类号： C07D495/04 ,  A61K31/55

    摘要： The present invention provides a therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia comprising, as an active ingredient, a tricyclic compound represented by formula (I): [wherein R1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy or halogen; X1-X2-X3 represents CR5═CR6—CR7═CR8, N(O)m═CR6—CR7═CR8, CR5═CR6—N(O)m═CR8, CR5═CR6—CR7═N(O)m, CR5═CR6—O, CR5═CR6—S, O—CR7═CR8, S—CR7═CR8 or O—CR7═N; Y represents 13 CH2S—, —CH2SO—, —CH2SO2—, —CH2O—, —CH═CH—, —(CH2)p—, —SCH2—, —SOCH2—, —SO2CH2— or —OCH2—; and R2 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy, amino, mono(substituted or unsubstituted lower alkyl)-substituted amino, di(substituted or unsubstituted lower alkyl)-substituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkylamino, substituted or unsubstituted arylamino or a substituted or unsubstituted heteroalicyclic group] or a pharmaceutically acceptable salt thereof.

    Remedies for vesical hyperactivity
    4.
    发明授权
    Remedies for vesical hyperactivity 失效
    用于膀胱活动过度的补救措施

    公开(公告)号：US07276532B2

    公开(公告)日：2007-10-02

    申请号：US10472143

    申请日：2002-03-29

    申请人： Tsuyoshi Yamagata ,  Kaoru Atsuki ,  Tetsuji Ohno ,  Shiro Shirakura ,  Akira Karasawa

    发明人： Tsuyoshi Yamagata ,  Kaoru Atsuki ,  Tetsuji Ohno ,  Shiro Shirakura ,  Akira Karasawa

    IPC分类号： A61K31/38

    CPC分类号： C07D495/04 ,  A61K31/55 ,  C07D337/12

    摘要： The present invention provides a therapeutic agent for overactive bladder comprising, as an active ingredient, a tricyclic compound represented by formula (I): [wherein R1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like; X1—X2—X3 represents CR5═CR6—CR7═CR8, CR5═CR6—S, and the like; Y represents —CH2S—, —SOCH2—, and the like; and R2 represents a hydrogen atom, and the like] or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明提供一种活性过氧化物的治疗剂，其包含作为活性成分的由式（I）表示的三环化合物：其中R 1表示氢原子，取代或未取代的低级烷基，和 类似; X 1 - 2 - - - - - - - - - - - - - - - - - - （3） CR 7 -CR 8，CR 5 -CR 6 -S等; Y表示-CH 2 -S-，-SOCH 2 - 等; 和R 2表示氢原子等]或其药学上可接受的盐。

    Xanthine derivatives
    7.
    发明授权
    Xanthine derivatives 失效
    黄嘌呤衍生物

    公开(公告)号：US5290782A

    公开(公告)日：1994-03-01

    申请号：US839690

    申请日：1992-02-24

    申请人： Fumio Suzuki ,  Junichi Shimada ,  Akio Ishii ,  Tetsuji Ohno ,  Akira Karasawa ,  Kazuhiro Kubo ,  Hiromi Nonaka

    发明人： Fumio Suzuki ,  Junichi Shimada ,  Akio Ishii ,  Tetsuji Ohno ,  Akira Karasawa ,  Kazuhiro Kubo ,  Hiromi Nonaka

    IPC分类号： C07D473/06 ,  C07D473/08 ,  C07D473/20 ,  C07D473/22 ,  C07D473/02 ,  A61K31/52

    CPC分类号： C07D473/06 ,  C07D473/08 ,  C07D473/20 ,  C07D473/22

    摘要： Novel xanthine compounds represented by the following formula: ##STR1## wherein each of X.sup.1 and X.sup.2 independently represents oxygen or sulfur; and Q represents; ##STR2## where ----- represents a single bond or a double bond; Y represents a single bond or alkylene, n represents 0 or 1, each of W.sup.1 and W.sup.2 independently represents hydrogen, lower alkyl or amino, Z represents --CH.sub.2 -, --O--, --S-- or --NH--; represents ##STR3## each of R.sup.1 and R.sup.2 independently represents hydrogen, lower alkyl, allyl or propargyl; and R.sup.3 represents hydrogen or lower alkyl, and when Q represents the groups other than ##STR4## each of R.sup.1, R.sup.2 and R.sup.3 independently represents hydrogen or lower alkyl;provided that when Q is ##STR5## then R.sup.1 R.sup.2 and R.sup.3 are notsimultaneously methyl; and pharmaceutically acceptable salts thereof have a diuretic effect, a renal-protecting effect and a bronchodilatory effect.

    摘要翻译： 由下式表示的新型黄嘌呤化合物：其中X1和X2各自独立地表示氧或硫; 和Q表示; 其中-----表示单键或双键; Y表示单键或亚烷基，n表示0或1，W1和W2各自独立地表示氢，低级烷基或氨基，Z表示-CH2 - ， - O - ， - S-或-NH-。 R1和R2各自表示氢，低级烷基，烯丙基或炔丙基; 且R 3表示氢或低级烷基，并且当Q表示除R1之外的基团时，R 1，R 2和R 3各自独立地表示氢或低级烷基; 条件是当Q为时，则R1 + L，R2和R3不同时为甲基; 及其药学上可接受的盐具有利尿作用，肾脏保护作用和支气管扩张作用。